The Seiden Group Announces U.S. Shareholders Formation Of A Group To Recover Investor Funds Through A Possible Receivership Over China-Based Bio-pharm Asia, Inc., (Ticker:BFAR)

Mar 21, 2017

BioPharm Asia, Inc., (ticker:”BFAR”), is a Nevada corporation involved in the sale of medical products to drug stores, hospitals, neighborhood clinics, and other medicine retail outlets in the People’s Republic of China. BFAR was de-listed from the NASDAQ in June 2013 after it stopped reporting to the Securities & Exchange Commission (“SEC”).

Certain shareholders have spoken with Robert W. Seiden, Esq. in New York to represent a group of shareholders to enforce the rights of the U.S. shareholders for acts detrimental to the investors including failure to report to the SEC in order to get a possible return of capital to the investors. . .

Read More


Olivia Johann
Business Development Lead
(646) 766-1704
[email protected]